Introduction
============

Kawasaki disease (KD), first described in 1967 by Kawasaki ([@b1-mmr-17-02-2402]), is a type of acute vasculitis with unknown etiology; however, KD is known to induce pathological alterations in medium-sized arteries, particularly coronary arteries. Some patients with KD develop coronary artery lesions and exhibit similar clinical outcomes to those of patients with coronary atherosclerosis ([@b2-mmr-17-02-2402]). Several studies have demonstrated that patients without coronary artery lesions still exhibit a high risk of various diseases, such as atherosclerosis, in adulthood ([@b2-mmr-17-02-2402]--[@b4-mmr-17-02-2402]). KD is a main cause of acquired heart disease in children, predominantly affecting coronary arteries ([@b5-mmr-17-02-2402]).

Without routine therapy, \~25% of patients with KD develop coronary artery dilation or aneurysms (CAD or CAA, respectively) ([@b6-mmr-17-02-2402]). Mild CAD can regress, while CAA and severe CAD are difficult to restore to a normal state. Mueller *et al* ([@b7-mmr-17-02-2402]) reported that patients with coronary artery sizes of ≤5.0 mm exhibited regression to the normal state, while patients with coronary artery sizes of \>5.0 mm exhibited persistence or even increases in size. CAA with a diameter of ≥8.0 mm is strongly associated with the development of coronary artery stenosis and myocardial infarction ([@b7-mmr-17-02-2402]).

These results indicate that KD may exert long-term effects on the coronary artery and cause pathophysiological insults of the cardiovascular system leading to CAD or CAA. To further understand complications in patients with KD, it is important to investigate the mechanisms of CAD and CAA formation, and to characterize the differences among normal coronary arteries, CAA and CAD. Coronary artery specimens are optimal for CAD and CAA studies; however, they are difficult to collect from patients with KD. Thus, blood samples were used in the present study.

Rapid advances in mass spectrometry (MS) for peptide identification and improved protein sequence coverage of complex biological samples ([@b8-mmr-17-02-2402]) has provided highly effective proteomic technologies for biomarker identification and therapeutic target discovery in serum samples ([@b9-mmr-17-02-2402],[@b10-mmr-17-02-2402]). In order to obtain accurate and reliable results, isobaric tags for relative and absolute quantitation (iTRAQ) and MS were employed for quantitative proteomics analyses, with increased proteome coverage and labelling efficiency to compare proteomes among serum samples from healthy individuals, and patients with KD and CAD or CAA ([@b6-mmr-17-02-2402]). Western blotting was employed to confirm the significantly expressed proteins following bioinformatics analysis. The objective of the present study was to investigate proteomic variations to further our current understanding of the pathogenesis of coronary artery lesions, and provide a basis for the establishment of indicators for these KD complications.

Materials and methods
=====================

### Preparation of serum samples

Blood samples were collected from 51 children (≤6 years old) who recruited to the present study ([Table I](#tI-mmr-17-02-2402){ref-type="table"}). Written informed consent was obtained from the guardians of each participant and the present study was approved by the Ethical Committee of Guangzhou Women and Children\'s Medical Center \[(2013)077; Guangdong, China\] based on the Japanese Ministry of Health and Welfare criteria, and the American Heart Association ([@b6-mmr-17-02-2402],[@b11-mmr-17-02-2402]). A total of 17 age- and sex-matched samples obtained from normal children, served as the controls; individuals were physically examined in Guangzhou Women and Children\'s Medical Center. The other 34 samples (17 CAA and 17 CAD) were obtained from patients who were diagnosed and excluded of other possible diseases by ≥2 pediatric cardiologists. Blood samples were separated by centrifugation at 1,000 × g for 10 min at 4°C and aliquots of serum were collected and stored at −80°C. Serum samples were processed to remove albumin and immunoglobulin G (IgG) using a ProteoPrep Blue Albumin and IgG Depletion kit (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). The concentrations of these proteins were determined using a Bradford protein assay kit (Bio-Rad Laboratories Inc., Hercules, CA, USA). These protein samples were randomly combined into 17 comparison groups, each of which included 1 control sample, 1 CAA sample and 1 CAD sample. Of the 17 comparison groups, 5 were randomly chosen and pooled together according to each type of sample; 3 pooled samples of the control, CAA and CAD groups were produced, and were subsequently analyzed by iTRAQ (Sciex, Framingham, MA, USA) experiments ([Table IA](#tI-mmr-17-02-2402){ref-type="table"}). The other 12 groups out of the total 17 were analyzed via western blotting. Information regarding the groups and diagnosis is presented in [Table IB](#tI-mmr-17-02-2402){ref-type="table"}.

### Protein identification and analysis

iTRAQ labeling was performed according to the manufacturer\'s instructions (Sciex). Briefly, 100 µg of each protein sample was reduced with Tris(2-carboxyethyl)phosphine hydrochloride reducing reagent (Sciex) at 60°C for 1 h, and alkylated with methyl methanethiosulfonate cysteine-blocking reagent (Sciex) for 30 min at room temperature. Then, proteins were digested with 2% trypsin (Promega Corporation, Madison, WI, USA) at 37°C overnight, at a ratio of 1:50 (enzyme-to-substrate). Each sample was labelled separately with the iTRAQ tags (118 tag for control, 113 tag for CAA and 116 tag for CAD), then dehydrated by centrifugation at 6,000 × g for 4 h at 25°C in a vacuum centrifuge.

iTRAQ-labelled samples were firstly diluted to 100 µl with H~2~O buffer (NH3•H~2~O, pH=10) prior to high performance liquid chromatography on a Dionex Ultimate 3000 system (Dionex, Sunnyvale, CA, USA) at 25°C on a Gemini-NX 3u C18 110A; 150×2.00 mm Phenomenex column, and Gemini 3u C6-Phenyl 110A; 100×2.0 mm column (all from Phenomenex, Torrance, CA, USA). The flow rate used for reversed-phase column separation was 0.2 ml/min with H~2~O (mobile phase A) and 80% acetonitrile (mobile phase B) with the following gradient system parameters: 5--10% B for 0--15 min, 15--28% B for 15--48 min, 25--37% B for 48--60 min, 37--95% B for 60--65 min and 95% B for 65--70 min. The elution was monitored by absorbance at 214/280 nm and the fractions were collected every 50 sec; these were pooled for each sample and dehydrated by centrifugation at 6,000 × g for 4 h at 25°C in vacuum centrifugation.

Peptides were separated with mobile phase A (0.1% formic acid), and 5--40% mobile phase B (0.1% formic acid and 80% acetonitrile) for 99 min (0.3 ml/min flow rate). MS analysis was performed on a Q Exactive hybrid quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, Inc., Waltham, MA, USA) with the following parameters: MS spectra were acquired across the scan range of 350--1,800 m/z in high resolution mode (\>35,000) and 100 msec was accumulated per spectrum. A maximum of 20 precursors per cycle were chosen for fragmentation, with 120 msec set as the minimum accumulation time for each precursor and dynamic exclusion for 10 sec.

The database searching of MS raw data was conducted against the human protein database by ProteinPilot Software 5.0 (Sciex). The search parameters were set as: 'Cys alkylation', 'Methyl methanethiosulfonate', 'Digestion', 'Trypsin', ≤1 missed trypsin cleavage was allowed and the false discovery rate (FDR) was \<0.01.

### Gene Ontology (GO) term and pathway analysis

The Cytoscape plug-in ClueGO ([@b12-mmr-17-02-2402]) and ReactomeFIViz ([@b13-mmr-17-02-2402]) were applied for the differentially expressed proteins to process the Biological Process GO terms, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis ([www.genome.jp/kegg/](www.genome.jp/kegg/)). P\<0.05 and FDR \<0.01 were selected as threshold values for GO and KEGG pathway enrichment.

### Western blot analysis

Serum samples from 36 children (12 control, 12 CAA and 12 CAD) were randomly grouped into 12 sets (for Control, CAA and CAD; details are presented in [Table IB](#tI-mmr-17-02-2402){ref-type="table"}) for validation. Proteins from the sera of these patients were extracted and the concentrations were measured using lysis buffer (Beyotime Institute of Biotechnology, Haimen, China) and a Bradford protein assay kit (Bio-Rad Laboratories, Inc.). Following electrophoresis with 20 µg protein per lane via 12--15% SDS-PAGE, the separated proteins were transferred onto polyvinylidene fluoride (PVDF) membranes (Sigma-Aldrich; Merck KGaA) and blocked with 5% skimmed milk for 1 h at room temperature, then incubated with primary antibodies (1:1,000) against: Complement factor H (CFH; cat. no. ab133536), mannose-binding lectin 2 (MBL2; cat. no. ab203303), kininogen 1 (KNG1; cat. no. ab170475), fibronectin (FN1; cat. no. ab2413), antithrombin-III (SERPINC1; cat. no. ab126598) and β-actin (cat. no. ab8227) (all from Abcam, Cambridge, UK) overnight at 4°C. Subsequently, horse radish peroxidase goat anti-rabbit IgG (cat. no. ab6721, 1:2,000; Abcam) was applied to the primary antibody-treated PVDF membranes at room temperature for 2 h. The specific bands on these membranes were visualized using the SuperSignal chemiluminescence system (Promega Corporation).

Results
=======

### Characteristics of patients with KD

Blood samples were obtained from 51 children (including 17 controls, 17 patients with CAA, and 17 patients with CAD); basic diagnostic information is shown in [Table IA and B](#tI-mmr-17-02-2402){ref-type="table"}. The patients with KD were ≤6 years and had clear clinical features; the abnormal degree of coronary alteration revealed that some rare CAA samples were included. Representative echocardiographic images of patients with KD and CAD or CAA, and healthy individuals are presented in [Fig. 1](#f1-mmr-17-02-2402){ref-type="fig"}. [Fig. 1](#f1-mmr-17-02-2402){ref-type="fig"} shows that the diameter of the normal coronary artery was \<3 mm and the diameter of CAD was \<4 and \>3 mm and the diameter of CAA was \>5 mm. The maximum diameter of the coronary artery was indicated in the images.

### Trial profile and study design

A total of 51 samples were divided into 17 groups, each of which contained one control, one CAD and one CAA sample. Of the 17 groups, 5 were randomly selected and the samples from these groups were pooled based on the sample type for iTRAQ analyses in order to detect significantly differentially expressed proteins. The other 12 groups were analyzed via western blotting. All experiments and validation procedures are summarized in in [Fig. 2](#f2-mmr-17-02-2402){ref-type="fig"}.

### Identification of differentially expressed proteins in KD patients with CAA or CAD by iTRAQ

Three pooled samples of the control, CAA and CAD groups, were subjected to iTRAQ. As presented in [Fig. 2](#f2-mmr-17-02-2402){ref-type="fig"}, MS analysis was performed twice using the iTRAQ technique to ensure that reliable results were obtained; 392 and 389 proteins were identified as a result of the two independent experiments. In total, 301 proteins overlapped in the two experiments and were considered the final accurate detected, high-quality proteins for the differential expression analysis. A threshold change of 1.5-fold was established to identify differentially expressed proteins in comparisons between CAD and control samples or CAA and control samples. For comparisons between CAD and control samples, 37 upregulated proteins and 50 downregulated proteins were identified as differentially expressed. For comparisons between CAA and control samples, the numbers of upregulated and downregulated differentially expressed proteins were 33 and 32, respectively ([Tables II](#tII-mmr-17-02-2402){ref-type="table"} and [III](#tIII-mmr-17-02-2402){ref-type="table"}).

### Differentially expressed protein categorization and network modelling

The functions (i.e., biological processes) of these differentially expressed proteins were analyzed using ClueGO, a Cytoscape plug-in that integrates GO terms ([@b12-mmr-17-02-2402]). Pie charts were used to display the differences in the distribution of functional categories for differentially expressed proteins between KD patients with CAD and CAA ([Fig. 3A](#f3-mmr-17-02-2402){ref-type="fig"}). For the CAD vs. control comparison, 9 enriched processes were observed; however, only 4 processes were enriched in the CAA vs. control comparison. These results are presented as bar charts in [Fig. 3B](#f3-mmr-17-02-2402){ref-type="fig"}, which use the same color scheme as that of the pie charts. Analysis of the biological processes, as summarized in the two pie charts, notably demonstrated that the wound healing response and lipoproteins are involved in CAD and CAA. In a combined analysis of the corresponding CAA/CAD bar charts and pie charts, the main differentially expressed proteins were involved in the wounding response, and lipoprotein and cholesterol-associated processes, indicating that KD patients with CAA may suffer more harmful attacks in the coronary arteries or surrounding areas.

To comprehensively characterize the associations among significantly differentially expressed proteins in CAA and CAD, KEGG pathway enrichment analysis and signaling network modelling were employed using the Cytoscape plug-in ReactomeFIViz ([@b13-mmr-17-02-2402]) ([Fig. 4A](#f4-mmr-17-02-2402){ref-type="fig"}). The thresholds for pathway enrichment were defined as P\<0.05 and FDR \<1%. These enriched pathways were associated with bacterial and viral infection (e.g., *Staphylococcus aureus* infection), inflammatory responses (e.g., complement cascades and platelet activation) and other metabolic processes. Various bacteria and viruses have been reported as infectious agents of KD, such as *Staphylococcus aureus* ([@b14-mmr-17-02-2402]), which may explain the activation of the inflammatory response pathways. However, KD is a highly-complicated disease, and its etiology and pathology are still unclear. The infection and inflammatory response-associated sub-networks were extracted from the whole differentially expressed protein networks in KD and the sub-network was highly enriched for proteins in infectious and inflammatory pathways. Some of these have demonstrated a high correlation with KD; the expression levels of the fibrinogen γ chain, which belongs to the fibrinogen family, are associated with KD according to a previous study ([@b15-mmr-17-02-2402]). Thus, the sub-network generated was deemed to be associated with KD ([Fig. 4B](#f4-mmr-17-02-2402){ref-type="fig"}). The network proteins were divided into 5 modules (presented as nodes of different colors in the figure) according to different clusters; proteins that serve a core role in each module and have either not been investigated or have rarely been investigated in previous studies were identified. Specifically, CFH, MBL2, KNG1, FN1 and SERPINC1 were identified as primary candidates involved in CAA and CAD (presented as bigger nodes with red circles). CFH and MBL2 were associated with classical complement proteins (yellow and pink clusters), KNG1 and FN1 were associated with proteins correlated to KD (grey and green clusters), and SERPINC1 is as an inhibitor in a complement protein associated pathway (green cluster). These results clarified the differentially expressed proteins in CAA and CAD samples and the associations among proteins in the network.

### Validation of proteomics results

Alterations in the expression levels of proteins were validated by western blotting using CAD and CAA samples, and normal samples for comparison. Five proteins (CFH, MBL2, KNG1, FN1 and SERPINC1) were validated in 12 groups of samples (each including 1 control, 1 CAD and 1 CAA sample); the results for 5 of 12 validated groups are presented in [Fig. 5](#f5-mmr-17-02-2402){ref-type="fig"}. The protein expression results for the 5 proteins exhibited high specificity and were consistent with the proteomics results observed in the iTRAQ. In particular, MBL2 and CFH exhibited reduced expression levels within the CAD samples, and the opposite results were obtained for KNG and SERPINC1, in which the expression levels were downregulated within CAA samples. The expression levels of FN1 were downregulated in the CAD and CAA samples when compared with the control samples.

Discussion
==========

The increased risk of coronary artery complications in patients with KD results in increased morbidity and mortality. The pathological processes of coronary artery lesions include endothelial dysfunction, the destruction of the internal elastic lamina, thrombocytosis and hypercoagulability. CAD and CAA are the main complications of KD, and may cause cardiovascular events ([@b16-mmr-17-02-2402]). It is highly important to determine the mechanisms of CAD/CAA to prevent and treat these complications. In the present study, serum protein level differences between healthy volunteers, patients with CAD and patients with CAA were investigated. The results suggested that several pathways, including those involved in the response to wounding, lipoprotein remodeling, platelet activation and blood coagulation, may differ between healthy volunteers, patients with CAD and patients with CAA.

In the present study, differentially expressed proteins associated with the two coronary artery abnormalities, CAD and CAA, within patients with KD were identified using proteomics methods. A total of 51 samples were divided into 17 groups. Each group contained 1 control sample, 1 CAD sample and 1 CAA sample. Three pooled samples (5 control, 5 CAD and 5 CAA) were generated by combining samples from 5 groups and were used for iTRAQ analyses to detect significantly differentially expressed proteins. The other 12 groups were used for western blot validation. In total, 87 and 65 differentially expressed proteins for the CAD and CAA were obtained, respectively, compared with the control.

The biological processes associated with differentially expressed proteins in CAD and CAA were also analyzed. Variations between the two conditions were identified in the present study; lower representation of proteins associated with the wounding response, lipoprotein modelling, platelet activation and blood coagulation, revealed that patients with KD and CAD may exhibit stress responses associated with coronary artery injury. However, within CAA patients, the representation of proteins involved in the response to wounding and the corresponding cholesterol components increased significantly with respect to control samples, indicating aggravated injury in coronary arteries. All of the identified significant proteins were used to construct a signaling network to clarify the overall pathway associations. The main pathways were enriched for functions in infection and immune associated diseases, inflammation and metabolism. These results are consistent with a previous hypothesis ([@b17-mmr-17-02-2402],[@b18-mmr-17-02-2402]). Thus, the present study focused on the infection, inflammation and coagulation pathways, which were extracted from the above network as a novel network for further analyses.

As presented in [Fig. 3B](#f3-mmr-17-02-2402){ref-type="fig"}, a few proteins in this network have been reported in previous studies associated with KD, including complement C3 (C3) ([@b19-mmr-17-02-2402]), apolipoprotein A-I ([@b20-mmr-17-02-2402]), and fibrinogen β chain ([@b21-mmr-17-02-2402]). Accordingly, the focus of the present study was on significant proteins that have not been reported previously and served key roles in each cluster of the network. Thus, the five proteins, CFH, MBL2, KNG1, FN1 and SERPINC1 were selected as candidate proteins associated with CAD and CAA. The western blot results for the five proteins were consistent with those of the iTRAQ analyses. MBL2 and CFH were reduced in KD with CAD compared with controls. KNG1 and SERPINC1 were downregulated in KD with CAA. FN1 was differentially expressed in both diseases; FN1 decreased in CAA and CAD when compared with controls.

CFH and MBL2 were in the complement protein-associated part of the network. Complement proteins, similar to the defense and clearance systems, serve an important role in the innate immune system. Pathogens activate the main complement protein C3 via one of the classical complement proteins, such as lectin, or alternative pathways to form C3b. The process is regulated to avoid excessive C3b production, which damages host cells, or a C3b deficiency, which induces an immune-compromised state via the main regulatory complement factor CFH ([@b22-mmr-17-02-2402]). MBL2 is a macromolecule that contains sugar-binding lectin and collagenous domains, and forms MBL-associated serine proteases to cleave complement proteins C2 and C4. The complex process is also known as the MBL pathway. A reduced level of MBL is associated with increased bacterial or viral infections in children, and MBL is known to serve a dual role in KD. Within children \<1-year-old, MBL may be associated with the resistance of infections, and in older children, MBL may be associated with endothelial damage ([@b23-mmr-17-02-2402]). Decreases in CFH and MBL2 were only observed in KD with CAD samples, which suggested a dysfunction in the complement system.

KNG1 and SERPINC1 are located in a coagulation-associated network. To the best of our knowledge, the direct genetic interactions of KNG1 with histidine-proline rich glycoprotein (HRG) and coagulation factor XII have never been reported in previous KD studies. However, some studies have indicated that they may interact with each other in the coagulation pathway. KNG1 and HRG have similar structures and are adjacent to each other on chromosome 3, which suggests that these proteins may exhibit similar functions ([@b24-mmr-17-02-2402],[@b25-mmr-17-02-2402]). HRG deficiency is associated with enhanced blood coagulation, which indicates that decreased KNG1 is a potential cofactor to enhance coagulation ([@b26-mmr-17-02-2402]). The potent anticoagulant SERPINC1 is a coagulation protease inhibitor and also possesses independent anti-inflammatory properties. Overexpressed SERPINC1 stimulates the expression of Coagulation Factor II and other proteases ([@b27-mmr-17-02-2402]). The protein is mainly associated with the diseases, inherited thrombophilia ([@b28-mmr-17-02-2402]) and SERPINC1 deficiency ([@b29-mmr-17-02-2402]), by affecting the anticoagulation pathways. The downregulation of KNG1 and SERPINC1 observed in KD with CAA samples may increase blood coagulation to enhance thrombosis.

FN1 is a multifunctional glycoprotein that serves in the plasma and extracellular matrix as a soluble dimer, or at the cell surface as a dimer or multimer. It participates in multiple biological processes, including cell adhesion, migration, wound healing, and blood coagulation ([@b30-mmr-17-02-2402]). Both CAD and CAA are characterized by endothelial dysfunction and stress responses to wound healing. Therefore, the decrease in FN1 expression levels in patients with coronary artery lesions may be associated with the aforementioned pathways.

In conclusion, the present study identified five candidate proteins differentially expressed in patients with KD and CAD/CAA: CFH, MBL2, KNG1, FN1 and SERPINC1. These five proteins provide a basis for understanding the differences between CAD and CAA in patients with KD. The alterations in MBL2 and CFH indicated that responses to pathogen infections and the innate immune system may be closely associated with the development of CAD. Decreased levels of KNG1 and SERPINC1 revealed that dysfunctions in coagulation accompanied the development of CAA. Decreased FN1 expression levels in the two conditions indicated that the pathways, including cell adhesion, migration, wound healing and blood coagulation may serve a role in the occurrence of CAD and CAA. The five proteins investigated in the present study may also serve to distinguish CAD and CAA in the early diagnosis of KD.
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![ECG images of coronary arteries from healthy individuals and patients with Kawasaki disease. Representative ECG images from (A) three children with normal left and right coronary arteries (controls); (B) three patients with CAD; and (C) three patients with CAA. ECG, echocardiography; CAA, coronary artery aneurism; CAD, coronary artery dilation; LCA, left coronary artery; RCA, right coronary artery.](MMR-17-02-2402-g00){#f1-mmr-17-02-2402}

![Flow diagram showing the trial profile and study design. CAA, coronary artery aneurism; CAD, coronary artery dilation; iTRAQ, isobaric tags for relative and absolute quantitation.](MMR-17-02-2402-g01){#f2-mmr-17-02-2402}

![Biological process of differentially expressed proteins in KD with CAD and CAA. (A) Pie charts representing the distribution of identified differentially expressed proteins according to their biological process. (B) Bar charts demonstrating the specific processes that correspond to the classification; the same color key that was used in the pie charts has also been applied in these charts. P\<0.05 was used as a threshold for gene ontology categories enrichment. KD, Kawasaki disease; CAA, coronary artery aneurism; CAD, coronary artery dilation.](MMR-17-02-2402-g02){#f3-mmr-17-02-2402}

![Network of differentially expressed proteins in KD with CAD and CAA. (A) Network based on functionally-enriched KEGG pathways. The proteins in the network were differentially expressed proteins in the present study. (B) Network associated with the variations within patients with KD and CAD/CAA. CFH (yellow cluster), MBL2 (pink cluster), KNG1 (grey cluster), FN1 (green cluster) and SERPINC1 (green cluster) were identified as primary candidates involved in CAA and CAD (presented as bigger nodes with red circles). P\<0.05 was a threshold for KEGG pathway enrichment. KD, Kawasaki disease; CAA, coronary artery aneurism; CAD, coronary artery dilation; KEGG, Kyoto Encyclopedia of Genes and Genomes; FN1, fibronectin 1; CFH, complement factor; KNG1, kininogen 1; MBL2, mannose binding lectin 2; SERPINC1, serpin family C member 1; FDR, false discovery rate.](MMR-17-02-2402-g03){#f4-mmr-17-02-2402}

![Protein expression confirmation of MBL2, CFH, KNG1, SERPINC1 and FN1 by western blotting in 5 representative groups comprised of healthy children (control), patients with KD and CAD, and patients with KD and CAA. CAA, coronary artery aneurism; CAD, coronary artery dilation; KD, Kawasaki disease; FN1, fibronectin 1; CFH, complement factor; KNG1, kininogen 1; MBL2, mannose binding lectin 2; SERPINC1, serpin family C member 1.](MMR-17-02-2402-g04){#f5-mmr-17-02-2402}

###### 

Clinical indicators of patients with Kawasaki disease.

  Patient                                            Age (years)         Sex       WBC count (10^9^/1)       N/L       CRP (mg/1)       ALT (U/1)       AST (U/1)       Coronary change (mm)
  -------------------------------------------------- ------------------- --------- ------------------------- --------- ---------------- --------------- --------------- --------------------------
  Patient-1 CAA-1                                    11 months           Female    11.3                        0.50    13.31            50              37              LCA=5.8, RCA=5.7
  Patient-2 CAA-2                                    2 years, 5 months   Male      17.7                        3.13    88.80            26              18              LCA=9.7, RCA=7.5
  Patient-3 CAA-3                                    1 year, 11 months   Male      10.5                        0.88      0.21           19              35              LCA=12, RCA=8.3
  Patient-4 CAA-4                                    1 year, 3 months    Male      22.8                        1.20    27.37              8             18              LCA=5.6, RCA=6.0
  Patient-5 CAA-5                                    2 months            Male      24.8                        1.75    71.51            36              24              LCA=4.0, RCA=4.6
  Patient-1 CAD-1                                    2 years, 7 months   Male      23.4                        5.25    211.13             7             12              LCA=3.2, RCA=3.7
  Patient-2 CAD-2                                    3 years             Male      14.6                      11.35       9.50           10              23              LCA=3.2, RCA=2.8
  Patient-3 CAD-3                                    3 years             Male      11.6                        4.15    45.12            14              30              LCA=4.0, RCA=3.7
  Patient-4 CAD-4                                    1 year, 1 month     Male      10.0                        4.72    93.30            161             32              LCA=2.9, RCA=3.4
  Patient-5 CAD-5                                    3 months            Female    20.5                        1.26    98.60            18              25              LCA=3.5, RCA=3.9
                                                                                                                                                                        
  **B, Patients for western blotting experiments**                                                                                                                      
                                                                                                                                                                        
  **Patient**                                        **Age (years)**     **Sex**   **WBC count (10^9^/1)**   **N/L**   **CRP (mg/1)**   **ALT (U/1)**   **AST (U/1)**   **Coronary change (mm)**
                                                                                                                                                                        
  Patient-6 CAA-6                                    1 year 3 months     Male      24.3                        1.71    175.60           19              26              LCA=4.0, RCA=4.5
  Patient-7 CAA-7                                    4 months            Male      34.7                        2.95    75.05            20              26              LCA=4.8, RCA=3.3
  Patient-8 CAA-8                                    6 years             Female    15.5                        3.77    68.57            26              21              LCA=6.6, RCA=3.1
  Patient-9 CAA-9                                    6 months            Male      13.31                       1.09    46.06            17              20              LCA=3.7, RCA=4.6
  Patient-10 CAA-10                                  8 months            Male      15.6                        1.60    146.70           20              16              LCA=3.3, RCA=4.2
  Patient-11 CAA-11                                  2 months            Male      17.0                        1.62    39.90            19              17              LCA=4.3, RCA=4.0
  Patient-12 CAA-12                                  2 months            Male      15.4                        1.85    18.18            14              17              LCA=3.8, RCA=4.6 m
  Patient-13 CAA-13                                  3 years             Male        7.0                       0.48      0.23           22              31              LCA=10.4, RCA=9.8
  Patient-14 CAA-14                                  1 year, 2 months    Female    19.6                        2.82    202.37           16              19              LCA=4.6, RCA=5.3
  Patient-15 CAA-15                                  4 months            Female    23.1                        1.42    110.05           40              42              LCA=3.8, RCA=4.5
  Patient-16 CAA-16                                  7 months            Male      17.5                        1.67    87.36              8             19              LCA=5.0, RCA=5.4
  Patient-17 CAA-17                                  1 year              Female    20.8                        1.76    58.00            11              21              LCA=5.0, RCA=3.6
  Patient-6 CAD-6                                    1 year, 1 month     Male      12.6                        0.43    73.13            35              30              LCA=3.1, RCA=2.8
  Patient-7 CAD-7                                    4 months            Male      13.7                        2.12    113.75           27              23              LCA=3.2, RCA=2.0
  Patient-8 CAD-8                                    4 years             Male      19.8                        7.26    59.22            73              20              LCA=3.4, RCA=3.1
  Patient-9 CAD-9                                    6 months            Male      21.5                        5.37    71.00            50              38              LCA=2.8, RCA=1.9
  Patient-10 CAD-10                                  7 months            Male      12.1                        0.99    78.10            14              19              LCA=2.5, RCA=2.0
  Patient-11 CAD-11                                  3 months            Female      9.7                       0.47    15.57            84              66              LCA=2.2, RCA=1.5
  Patient-12 CAD-12                                  2 months            Male      24.5                      12.26     209.63           24              24              LCA=2.5, RCA=2.1
  Patient-13 CAD-13                                  2 years, 9 months   Male        7.3                       1.58    29.98            23              23              LCA=3.4, RCA=2.8
  Patient-14 CAD-14                                  7 months            Male      24.1                        1.91    55.72            13              20              LCA=2.7, RCA=2.8
  Patient-15 CAD-15                                  7 months            Male      17.6                        0.83    44.60            18              19              LCA=3.0, RCA=2.4
  Patient-16 CAD-16                                  4 years             Male      22.3                        9.16    147.85           136             39              LCA=3.0, RCA=2.6
  Patient-17 CAD-17                                  1 year, 1 month     Male      17.5                        7.79    144.10           82              44              LCA=3.5, RCA=2.9

CAA, coronary artery aneurism; CAD, coronary artery dilation; WBC, white blood cell; N/L, neutrophils/lymphocytes; CRP, C-reactive protein; ALT, alanine transaminase; AST, aspartate aminotransferase; LCA, left coronary artery; RCA, right coronary artery; iTRAQ, isobaric tags for relative and absolute quantitation.

###### 

Identification of differentially expressed proteins between the Kawasaki disease with coronary artery dilation and control groups by isobaric tags for relative and absolute quantitation technology.

  Protein name                                                             Gene name    Accession nos.   95% CI    Peptides (95%)   Unused ProtScore   Ratio (Con/CAD)
  ------------------------------------------------------------------------ ------------ ---------------- --------- ---------------- ------------------ -----------------
  Complement C4-A                                                          C4A          P0C0L4           59.46     263              176.2                1.9953
  α-1-antitrypsin                                                          SERPINA1     P01009           87.32     357              147.8                3.4041
  Haptoglobin                                                              HP           P00738           83.25     426              125.86               6.4269
  Uncharacterized protein                                                  N/A          B4E1Z4           47.47     105              100.21               3.4356
  Hemopexin                                                                HPX          P02790           74.24     155              82.36                2.3121
  α-1-antichymotrypsin                                                     SERPINA3     P01011           67.38     119              66.07                9.0365
  α-1-acid glycoprotein 1                                                  ORM1         P02763           55.22       90             44.86                7.5162
  Plasma protease C1 inhibitor                                             SERPING1     P05155           47.80       61             44.05                3.5318
  Complement component C9                                                  C9           P02748           38.82       34             40.08                9.6383
  Inter-α-trypsin inhibitor heavy chain H3                                 ITIH3        Q06033           29.10       53             34.19                2.4434
  Ig α-1 chain C region                                                    IGHA1        P01876           58.36       92             33.33                2.5119
  Leucine-rich α-2-glycoprotein                                            LRG1         P02750           43.80       27             23.89                4.9204
  Hemoglobin subunit β                                                     HBB          P68871           88.44       41             21.25                3.0200
  Angiotensinogen                                                          AGT          P01019           25.77       21             20.46                9.7275
  Fibrinogen α chain                                                       FGA          P02671           25.17       21             19.87                9.3756
  Plastin-2                                                                LCP1         P13796           21.37       11             18.50                1.6596
  Lipopolysaccharide-binding protein                                       LBP          P18428           23.70       10             18.31                3.6983
  Fibrinogen γ chain                                                       FGG          C9JEU5           33.26       11             17.56                2.5119
  α-1-acid glycoprotein 2                                                  ORM2         P19652           49.75       43             17.51                6.4269
  Hemoglobin subunit α                                                     HBA1         P69905           67.61       40             16.75                5.2966
  Fibrinogen β chain                                                       FGB          P02675           27.09       11             13.20                2.8314
  Monocyte differentiation antigen CD14                                    CD14         P08571           32.00         7            12.14                2.0512
  Serum amyloid A-1 protein                                                SAA1         P0DJI8           54.92       20             11.73                3.8019
  Serum amyloid P-component                                                APCS         P02743           31.39       12             11.02                2.4889
  Complement C4-B                                                          C4B          P0C0L5           59.12     257              10.00                1.7865
  Polymeric immunoglobulin receptor                                        PIGR         P01833           10.34         6              9.25               2.4210
  C-reactive protein                                                       CRP          P02741           16.52         8              8.53               8.3176
  Mannose-binding protein C                                                MBL2         P11226           16.53         4              7.33               2.5586
  Ig ∆ chain C region (fragment)                                           IGHD         A0A0A0MS09       16.05         5              6.96               5.2966
  Keratin, type I cytoskeletal 10                                          KRT10        P13645           11.82         5              6.66               2.2284
  Transgelin-2 (fragment)                                                  TAGLN2       X6RJP6           27.27         5              6.57               3.0479
  Protein S100-A9                                                          S100A9       P06702           30.7          3              6.39               4.9204
  α-1-antitrypsin                                                          SERPINA1     A0A024R6I7       87.32     348                5.19             46.1318
  Lymphatic vessel endothelial hyaluronic acid receptor 1                  LYVE1        Q9Y5Y7             5.59        2              4.00               2.0701
  Protein S100-A8                                                          S100A8       P05109           23.66         2              2.14               4.4463
  Protein IGLV2-11 (fragment)                                              IGLV2-11     A0A075B6K3         6.723       3                2                5.7544
  Resistin                                                                 RETN         Q9HD89           10.19         1                2                1.8707
  Apolipoprotein B-100                                                     APOB         P04114           51.92     374              399.96             −2.5586
  Serotransferrin                                                          TF           P02787           78.08     349              172.35             −1.8707
  Serum albumin                                                            ALB          P02768           74.88     271              139.74             −5.2966
  Fibronectin                                                              FN1          P02751           36.5      101              108.76             −30.4790
  Complement factor H                                                      CFH          P08603           50.93       85             92.38              −2.4660
  Complement C5                                                            C5           P01031           30.91       58             78.08              −2.0893
  Apolipoprotein A-I                                                       APOA1        P02647           78.28     162              65.7               −5.0582
  Inter-α-trypsin inhibitor heavy chain H1                                 ITIH1        P19827           45.77       81             56.95              −2.7040
  Plasminogen                                                              PLG          P00747           52.59       63             55.98              −4.4875
  Apolipoprotein A-IV                                                      APOA4        P06727           65.4        52             45.59              −1.5996
  Afamin                                                                   AFM          P43652           42.9        27             37.22              −2.4889
  Heparin cofactor 2                                                       SERPIND1     P05546           42.48       43             35.9               −3.3420
  Histidine-rich glycoprotein                                              HRG          P04196           38.67       27             35.14              −9.2897
  α-2-HS-glycoprotein                                                      AHSG         P02765           57.49       51             34.96              −1.9231
  Apolipoprotein A-II                                                      APOA2        V9GYM3           49.62       66             30.77              −5.1051
  Serum paraoxonase/arylesterase 1                                         PON1         P27169           59.44       35             30.46              −2.7040
  Apolipoprotein E                                                         APOE         P02649           56.78       38             26.73              −2.0512
  Gelsolin                                                                 GSN          P06396           25.45       24             24.19              −3.8371
  Complement component C8 β chain                                          C8B          F5H7G1           19.48       14             22.71              −2.5823
  Coagulation factor XII                                                   F12          P00748           26.5        21             21.87              −2.0893
  Coagulation factor XIII B chain                                          F13B         P05160           23.45       15             21.37              −1.9231
  Pigment epithelium-derived factor                                        SERPINF1     P36955           30.14       12             18.6               −1.9231
  Lumican                                                                  LUM          P51884           41.42       17             18.42              −1.5417
  β-2-glycoprotein 1                                                       APOH         P02749           43.19       16             18.2               −2.1677
  N-acetylmuramoyl-L-alanine amidase                                       PGLYRP2      Q96PD5           38.72       17             17.6               −2.3988
  Kallistatin                                                              SERPINA4     P29622           30.91       13             17.58              −3.1333
  Insulin-like growth factor-binding protein complex acid labile subunit   IGFALS       P35858           18.18       10             17.48              −2.6546
  Extracellular matrix protein 1                                           ECM1         Q16610           22.04       10             16.77              −2.1878
  Sex hormone-binding globulin                                             SHBG         P04278           39.55       10             16.18              −2.2699
  Transthyretin                                                            TTR          P02766           72.11       27             15.31              −3.0479
  Apolipoprotein L1                                                        APOL1        O14791           34.42       11             14.3               −2.3335
  Prenylcysteine oxidase 1                                                 PCYOX1       Q9UHG3           18.02         8              14               −3.1623
  Retinol binding protein 4, plasma, isoform CRA_b                         RBP4         Q5VY30           58.79       14             11.92              −3.6983
  Phosphatidylinositol-glycan-specific phospholipase D                     GPLD1        P80108           10.95         8            11.54              −3.6308
  Apolipoprotein M                                                         APOM         O95445           36.7        11             10.76              −3.5318
  Tetranectin                                                              CLEC3B       E9PHK0             55        10             10.58              −2.0893
  Protein IGHV3-53 (fragment)                                              IGHV3-53     A0A087WSX4       60.34       21             10.43              −1.9770
  Phospholipid transfer protein                                            PLTP         P55058           12.58         5            10.05              −1.8030
  Apolipoprotein(a)                                                        LPA          P08519           11.65         7              9.86             −2.8576
  Uncharacterized protein                                                  N/A          A0A0G2JPD4       71.04     150                9.19             −1.9055
  Vitamin K-dependent protein C                                            PROC         E7END6           10.1          5                8              −1.7378
  Cholesteryl ester transfer protein                                       CETP         P11597           10.14         6              6.52             −4.9659
  Fetuin-B                                                                 FETUB        Q9UGM5           13.87         4              6.26             −2.7040
  Apolipoprotein C-III                                                     APOC3        B0YIW2           34.19       11               6.18             −2.8840
  Uncharacterized protein                                                  N/A          A0A0G2JN06       55.05       79               6.03             −3.3729
  Protein IGHV1-69-2 (fragment)                                            IGHV1-69-2   A0A0B4J2H0       58.12       11                 6              −1.7061
  Apolipoprotein C-IV                                                      APOC4        P55056           15.75         2                4              −2.5823
  Apolipoprotein C-I (fragment)                                            APOC1        K7ERI9           23.38         2              2.84             −2.2699
  Urea transporter 2                                                       SLC14A2      Q15849             1.522       3                2              −3.4674
  Extracellular superoxide dismutase (Cu-Zn)                               SOD3         P08294             4.583       1              1.77             −1.6144

95% CI, percentage of matching amino acids from identified peptides having confidence intervals ≥95%, divided by the total number of amino acids in the sequence; Unused ProtScore, a measure of the protein confidence for a detected protein, calculated from the peptide confidence interval for peptides from spectra that are not already completely used by higher scoring winning proteins. Con, control group; CAD, coronary artery dilation group.

###### 

Identification of differentially expressed proteins between the Kawasaki disease with coronary artery aneurysm and control groups by isobaric tags for relative and absolute quantitation technology.

  Protein name                                           Gene name    Accession nos.   95% CI   Peptides (95%)   Unused ProtScore   Ratio (Con/CAA)
  ------------------------------------------------------ ------------ ---------------- -------- ---------------- ------------------ -----------------
  α-1-antitrypsin                                        SERPINA1     P01009           87.32    357              147.80               1.5996
  Haptoglobin                                            HP           P00738           83.25    426              125.86               7.1121
  Uncharacterized protein                                N/A          B4E1Z4           47.47    105              100.21               2.8576
  Ig µ chain C region                                    IGHM         A0A087WYJ9       64.94      98             68.73                1.6749
  α-1-antichymotrypsin                                   SERPINA3     P01011           67.38    119              66.07                4.3251
  α-1-acid glycoprotein 1                                ORM1         P02763           55.22      90             44.86                6.7920
  Complement component C9                                C9           P02748           38.82      34             40.08                6.3096
  Pregnancy zone protein                                 PZP          P20742           25.98    146              24.62                5.3951
  Leucine-rich α-2-glycoprotein                          LRG1         P02750           43.80      27             23.89                3.6983
  Angiotensinogen                                        AGT          P01019           25.77      21             20.46                2.2909
  Fibrinogen α chain                                     FGA          P02671           25.17      21             19.87              25.3513
  Lipopolysaccharide-binding protein                     LBP          P18428           23.70      10             18.31                4.4463
  Fibrinogen γ chain                                     FGG          C9JEU5           33.26      11             17.56              21.2814
  α-1-acid glycoprotein 2                                ORM2         P19652           49.75      43             17.51                6.1376
  Hemoglobin subunit a                                   HBA1         P69905           67.61      40             16.75                2.6303
  Galectin-3-binding protein                             LGALS3BP     Q08380           18.63      10             14.74                1.8535
  Fibrinogen β chain                                     FGB          P02675           27.09      11             13.20                9.2897
  Monocyte differentiation antigen CD14                  CD14         P08571           32.00        7            12.14                1.7219
  Serum amyloid A-1 protein                              SAA1         P0DJI8           54.92      20             11.73                3.8371
  Complement C4-B                                        C4B          P0C0L5           59.12    257              10.00                2.3335
  Apolipoprotein(a)                                      LPA          P08519           11.65        7              9.86               3.6644
  C-reactive protein                                     CRP          P02741           16.52        8              8.53               3.6644
  Hemoglobin subunit γ-2                                 HBG2         P69892           43.54        6              7.70               4.0179
  Transgelin-2 (fragment)                                TAGLN2       X6RJP6           27.27        5              6.57               3.3420
  Protein S100-A9                                        S100A9       P06702           30.70        3              6.39               5.2966
  Protein IGHV1-69-2 (fragment)                          IGHV1-69-2   A0A0B4J2H0       58.12      11               6.00               2.4660
  α-1-antitrypsin                                        SERPINA1     A0A024R6I7       87.32    348                5.19             29.1072
  Protein IGLV3-19 (fragment)                            IGLV3-19     A0A075B6J8       70.54        7              4.66               2.9107
  Protein IGLV7-46 (fragment)                            IGLV7-46     A0A075B6I9       15.38        3              3.04               1.6596
  HCG1782423 (fragment)                                  IGLV2-18     A0A075B6J9       24.17        2              2.63               3.3113
  Protein S100-A8                                        S100A8       P05109           23.66        2              2.14               4.8306
  Ras-related protein Rap-1b (fragment)                  RAP1B        F5H823           17.48        2              2.00               2.2699
  Serglycin                                              SRGN         P10124             8.23       1              2.00               1.6444
  Serotransferrin                                        TF           P02787           78.08    349              172.35             −8.5507
  Serum albumin                                          ALB          P02768           74.88    271              139.74             −3.6983
  Fibronectin                                            FN1          P02751           36.50    101              108.76             −3.8726
  Apolipoprotein A-I                                     APOA1        P02647           78.28    162              65.70              −3.1623
  Inter-α-trypsin inhibitor heavy chain H1               ITIH1        P19827           45.77      81             56.95              −2.0137
  Plasminogen                                            PLG          P00747           52.59      63             55.98              −2.5119
  Kininogen-1                                            KNG1         P01042           45.19      73             54.56              −2.3121
  Apolipoprotein A-IV                                    APOA4        P06727           65.40      52             45.59              −2.7290
  Antithrombin-III                                       SERPINC1     P01008           43.75      46             44.44              −2.0893
  Afamin                                                 AFM          P43652           42.90      27             37.22              −1.9953
  Histidine-rich glycoprotein                            HRG          P04196           38.67      27             35.14              −2.8054
  α-2-HS-glycoprotein                                    AHSG         P02765           57.49      51             34.96              −2.2699
  Apolipoprotein A-II                                    APOA2        V9GYM3           49.62      66             30.77              −3.3420
  Serum paraoxonase/arylesterase 1                       PON1         P27169           59.44      35             30.46              −2.0512
  Apolipoprotein E                                       APOE         P02649           56.78      38             26.73              −1.7378
  Gelsolin                                               GSN          P06396           25.45      24             24.19              −1.8707
  Coagulation factor XII                                 F12          P00748           26.50      21             21.87              −1.8030
  Protein AMBP                                           AMBP         P02760           31.25      24             18.34              −2.2284
  Kallistatin                                            SERPINA4     P29622           30.91      13             17.58              −2.1281
  Extracellular matrix protein 1                         ECM1         Q16610           22.04      10             16.77              −1.6596
  Transthyretin                                          TTR          P02766           72.11      27             15.31              −2.8576
  Apolipoprotein L1                                      APOL1        O14791           34.42      11             14.30              −1.8030
  Prenylcysteine oxidase 1                               PCYOX1       Q9UHG3           18.02        8            14.00              −1.7061
  Retinol binding protein 4, plasma, isoform CRA_b       RBP4         Q5VY30           58.79      14             11.92              −2.6303
  Phosphatidylinositol-glycan-specific phospholipase D   GPLD1        P80108           10.95        8            11.54              −1.8880
  Apolipoprotein M                                       APOM         O95445           36.70      11             10.76              −2.1086
  Tetranectin                                            CLEC3B       E9PHK0           55.00      10             10.58              −1.8030
  Cholinesterase                                         BCHE         P06276           10.96        7            10.56              −2.1281
  Keratin, type I cytoskeletal 10                        KRT10        P13645           11.82        5              6.66             −1.9953
  Apolipoprotein C-III                                   APOC3        B0YIW2           34.19      11               6.18             −2.7040
  Uncharacterized protein (fragment)                     N/A          A0A0C4DH43       24.37        3              4.00             −2.3768
  Urea transporter 2                                     SLC14A2      Q15849             1.52       3              2.00             −10.0000

95% CI, percentage of matching amino acids from identified peptides having confidence intervals ≥95%, divided by the total number of amino acids in the sequence; Unused ProtScore, a measure of the protein confidence for a detected protein, calculated from the peptide confidence interval for peptides from spectra that are not already completely used by higher scoring winning proteins; Con, control group; CAA, coronary artery aneurysm.
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